Viewing Study NCT03659136



Ignite Creation Date: 2024-05-06 @ 12:01 PM
Last Modification Date: 2024-10-26 @ 12:53 PM
Study NCT ID: NCT03659136
Status: COMPLETED
Last Update Posted: 2024-07-10
First Post: 2018-09-03

Brief Title: The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Sponsor: Boehringer Ingelheim
Organization: Boehringer Ingelheim

Study Overview

Official Title: XENERA1 A Multi-centre Double-blind Placebo-controlled Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR HER2- Metastatic Breast Cancer and Non-visceral Disease
Status: COMPLETED
Status Verified Date: 2024-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR HER2- advanced or metastatic breast cancer and non-visceral disease
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2017-003131-11 EUDRACT_NUMBER None None